World Bulk Paclitaxel Markets

Frost & Sullivan, September 2001

Organic-Based Drug Holds Tremendous Promise for Growing Cancer Patient Population

Paclitaxel, an antineoplastic agent derived from the Pacific Yew tree, is gaining
recognition as the most promising anticancer agent on the market, continually
out-performing other cancer therapies. In clinical trials, this drug has shown
remarkable success against advanced stages of ovarian and breast cancers. By
combining paclitaxel with other therapies, its potency and efficacy are greatly
enhanced. With global government agencies continuing to approve
combination therapies, physicians are increasingly prescribing paclitaxel to the
rising number of cancer patients.

This Frost & Sullivan analysis provides the most up-to-date information on the
world bulk paclitaxel markets. By identifying market drivers and offering
strategic recommendations for overcoming industry challenges, this study

allows reader to develop a tactical business platform for increasing market
share in this evolving field.

Dwindling Supply Drives Market Demand

As paclitaxel is a natural therapy extracted from the bark of the Pacific Yew, it
requires numerous trees to produce a sufficient supply. The environmental

impact on this slow growing resource has fueled concern from the medical
community as to the long-term availability of this product.

In the last couple of years, plant cell culture techniques and genetic

engineering have emerged as an effective technique to augment production,
says the author of this research. In spite of these developments, the threat of

diminishing stock has resulted in a rising demand by participants for adequate
quantities to support research, development, and treatment efforts.

Generics Market Opens New Opportunities for Participants

With the initial introduction of paclitaxel, one company stunned the market by

taking a proactive stance and blocking market competition through an
aggressive litigation strategy. For five years, this firm held exclusive rights to
the drug. However, in 2000, the U.S. Food and Drug Administration (FDA)
began granting market approval to competitors offering generic equivalents.
For a pharmaceutical manufacturer, launching a generic Taxol is an
opportunity not to be missed, says the author. Generic paclitaxel is expected

to be available at a lower cost and should boost the frequency that physicians
prescribe this drug, resulting in increased sales.

This Frost & Sullivan research provides in-depth intelligence on the world
bulk paclitaxel industry, enabling market participants to implement effective
investment strategies to capitalize on this emerging field.

Additional Information

Market Participants
9 Top Pharmaceutical Co.

Abbott Laboratories

Aphios Corporation
Angiotech, Inc.

British Technology Group
Cell Therapeutics, Inc.
Dabur India Ltd.
Enzon, Inc.
F.H. Faulding & Co. Ltd.
Guilford Pharmaceuticals, Inc.
Hauser, Inc.
IVAX Corp.
LDS Technologies, Inc.
MacroMed, Inc.
Matrix Pharmaceuticals, Inc.
Mylan Laboratories, Inc.
NaPro BioTherapeutics, Inc.
Natural Pharmaceuticals, Inc.

Natland International Corporation
NeoPharm, Inc.
Novopharm Biotech, Inc.
Novopharm Ltd.
N.V. Boehringer-Ingelheim SA
Pharmacia & Upjohn Co.
Phytogen Life Sciences, Inc.

Phyton Catalytica
Protarga, Inc.
Samyang Genex Corp.
Schein Pharmaceuticals, Inc.
Sonus Pharmaceuticals, Inc.
STS Particles, Inc./Medisperse
Supergen, Inc.
Taxalog, Inc.
Teva Pharmaceutical Industries, Ltd.

The Liposome Company
VivoRx Pharmaceuticals, Inc.

1. Executive Summary
A. Introduction to the Market for Bulk Paclitaxel Manufacturing

1. Summary of Major Findings

2. History of Paclitaxel Market

3. Bulk Paclitaxel Supply-Side Dynamics

4. Future Direction

5. Bristol-Myers Squibb Strategies to Dominate the Taxol Market

6. Examples of Partners for Bulk Paclitaxel Manufacturers

7. Competitive Analysis

8. Conclusion

2. Market Engineering Research Methodology: Market for Bulk Paclitaxel
A. Research Scope

1. Objectives and Purpose

2. Report Structure and Segmentation

3. Glossary of Terms

3. Industry Challenges
A. Identification of the Challenges Facing the World Market for Bulk Paclitaxel

1. Market Challenges

4. Market Analysis of the Market for Bulk Paclitaxel
A. Introduction to the Cancer Market

1. Introduction

2. Cancer Treatments

3. Paclitaxel

4. Prescribing Patterns of Oncologists

5. Market Engineering Research for the World Market for Bulk Paclitaxel
A. Total Market Segment Analysis

1. Market Overview

2. Market Engineering Research Measurement System

3. Market Engineering Units and Revenue Forecasts (1997-2007)

4. Market and Technology Trends

5. Pricing Strategies and Trends Analysis

6. Competitive Structure

7. Bulk Paclitaxel Process Analysis

6. Market Engineering Strategy
A. Conclusions and Recommendations

1. What Is Market Engineering Strategy?

2. Increased Demand

3. Market and Revenue Forecast

4. Market Opportunities

5. Industry Perceptions

6. Market Strategies

7. Market Niche

8. Winning Marketing Practices
B. Promotion of Companies and Technology

1. Introduction

2. Public Relations Infrastructure

3. Recommendations for Manufacturing

4. Alliances and Partnerships

5. Business Development and Brokerage

7. Profile of Companies Included in this Report
A. List of Companies

1. Bulk Manufacturers

2. Generic Pharmaceutical Manufacturers with Filed aNDA for Paclitaxel

3. Companies Developing New Formulation/Derivatives of Paclitaxel

List Of Figures

Chapter 2

Market for Bulk Paclitaxel: Countries that Violate the Patent Laws (World), 2000
Number of Years Nations Prevent Free Riding of Innovators: Safety and Effectiveness Data

Chapter 3

Market for Bulk Paclitaxel: Impact of Top Ten Industry Challenges (World), 2000-2007

Chapter 4

Prevalence, Treatment Costs and Drugs in Development for Selected Diseases (U.S.), 1999
Estimated New Cases and Deaths due to Cancer (U.S.), 1999
Estimated New Cases and Deaths due to Cancer--Continued (U.S.), 1999
Estimated New Cases and Deaths due to Cancer--Continued (U.S), 1999

Cancer Treatment Options

Types of Chemotherapy Drugs
Market for Bulk Paclitaxel: Vincristine (World), 2000
Market for Bulk Paclitaxel: Vinblastin (World), 2000
Market for Bulk Paclitaxel: Etoposide (World), 2000
Market For Bulk Paclitaxel: Paclitaxel (World), 2000
Market for Bulk Paclitaxel: Topetecan (World), 2000
Market for Bulk Paclitaxel: Docetaxel (World), 2000
Market for Bulk Paclitaxel: Vinorelbine (World), 2000
Market for Bulk Paclitaxel: Lung Cancer Pathology (World), 2000
Market for Bulk Paclitaxel: Common Drugs Used in the Treatment of Lung Cancer (World), 2000
Market for Bulk Paclitaxel: Breast Cancer Demographic Forecast (World), 2000-2007
Market for Bulk Paclitaxel: Chemotherapy Combinations for Breast Cancer (World), 2000
Market for Bulk Paclitaxel: Chemotherapy Combinations for Breast Cancer—Continued (World), 2000
Market for Bulk Paclitaxel: Chemotherapy Combinations for Breast Cancer—Continued (World), 2000
Market for Bulk Paclitaxel: Key Chemotherapy Agents Used in the Treatment of Breast Cancer (World), 2000
Market for Bulk Paclitaxel: Key Chemotherapy Agents Used in the Treatment of Breast Cancer--Continued (World), 2000
Market for Bulk Paclitaxel: Key Chemotherapy Agents Used in the Treatment of Breast Cancer--Continued (World), 2000
Market for Bulk Paclitaxel: Cost Analysis of the Most Commonly Used Cytotoxic Drug Combinations for Breast Cancer (World), 2000
Market for Bulk Paclitaxel: Dosage and Scheduling for Kaposi's Sarcoma (World), 2000
Market for Bulk Paclitaxel: Common Drugs Used in the Treatment of Ovarian Cancer (World), 2000
Market for Bulk Paclitaxel: Common Drugs Used in the Treatment of Ovarian Cancer-- Continued (World), 2000
Market for Bulk Paclitaxel: Cost breakdown of Paclitaxel, Docetaxel and Vinorelbine for the Treatment of Metastatic Breast Cancer (World), 2000
Market for Bulk Paclitaxel: Cost breakdown of Paclitaxel, Docetaxel and Vinorelbine for the Treatment of Breast Cancer—Continued (World), 2000

Chapter 5

Market for Bulk Paclitaxel: Revenue Forecast Based on Pricing and Units Sold (World), 2000-2007
Market for Bulk Paclitaxel: Market Drivers Ranked in Order of Impact (World), 2000-2007
Market for Bulk Paclitaxel: Market Restraints Ranked in Order of Impact (World), 2000-2007
Market for Bulk Paclitaxel: Companies That Have Filed a Drug Master File with the FDA (World), 2000
Market for Bulk Paclitaxel: Companies That Have Filed a Drug Master File with the FDA-- Continued (World), 2000
Market for Bulk Paclitaxel: Companies That Have Filed a Drug Master File with the FDA-- Continued (World), 2000
Market for Bulk Paclitaxel: Companies That Have Filed a Drug Master File with the FDA-- Continued (World), 2000
Market for Bulk Paclitaxel: Comparative Revenue Analysis (World), 1995-2000
Market for Bulk Paclitaxel: Market Share Analysis by Product (World), 1995-2000
Market for Bulk Paclitaxel: Bulk Paclitaxel Quantity Distributed (World), 2000-2007
Market for Bulk Paclitaxel: New Formulations of Paclitaxel (World), 2000
Market for Bulk Paclitaxel: Pricing Analysis (World), 2000-2007
Market for Bulk Paclitaxel: Competitive Structure (World), 2000
Market for Bulk Paclitaxel: Indena's Patent Estate (World), 2000
Market for Bulk Paclitaxel: NaPro Biotherapeutics Paclitaxel Revenue (World), 1993-2000
Market for Bulk Paclitaxel: NaPro Paclitaxel Sales to Faulding (World), 1995-2000
Market for Bulk Paclitaxel: Products Offered by Natland International Corporation (World), 2000
Market for Bulk Paclitaxel: Paclitaxel Products Offered by 9Top Natural Pharmaceutical Company (World), 2000
Market for Bulk Paclitaxel: Paclitaxel Products Offered by Jiangsu Medicine and Health Products Import and Export Group (World), 2000
Market for Bulk Paclitaxel: Paclitaxel Product Offered by Newport Pharmaceuticals Company (World), 2000
Market for Bulk Paclitaxel: Paclitaxel Product Offered by Han Kook Sin Yak Company (World), 2000
Market for Bulk Paclitaxel: Database of Key Industry Participants by Product and Certification (World), 2000
Market for Bulk Paclitaxel: Steps in Isolating Paclitaxel via Plant Cell Culture Technology (World), 2000

Chapter 6

Market for Bulk Paclitaxel: Comparative Analysis of Companies in the Paclitaxel Bulk Manufacturing Market (World), 2000

Customers who bought this item also bought

• Market of Paclitaxel Injection in China
• Non-Small-Cell Lung Cancer (Event Driven)
• Melanoma - Thought Leader Panel 2012
• Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
• Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types
• Oncology Intelligence: A Comprehensive Report for Decision Making
• Biomarker Technology Platforms for Cancer Diagnoses and Therapies
• Coronary Stents - Global Strategic Business Report
• Stakeholder Opinions: Melanoma Future treatment will be based on individual tumor gene expression signatures
• Molecular Diagnostics - Technologies, Markets and Companies